Rivus Pharmaceuticals, Inc.
11
1
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.1%
1 terminated/withdrawn out of 11 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Role: lead
Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6
Role: lead
Relative Bioavailability Study of HU6
Role: lead
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
Role: lead
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
Role: lead
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
Role: lead
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
Role: lead
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
Role: lead
Safety and Pharmacokinetics of HU6
Role: lead
Multiple Ascending Dose Study of HU6 in High BMI Volunteers
Role: lead
Ascending Dose Study of HU6 in Healthy Volunteers
Role: lead
All 11 trials loaded